Sulopenem Etzadroxil/Probenecid Market Size and Share Analysis Across 7MM and Competitive Landscape by DelveInsight | Key Players - Iterum Therapeutics and Pfizer

DelveInsight has released a comprehensive report titled "Sulopenem Etzadroxil/Probenecid Market Forecast" offering a thorough examination and predictive insights into the Sulopenem Etzadroxil/Probenecid market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The extensive report offers a thorough examination of the market potential and market share of Sulopenem Etzadroxil/Probenecid in the therapeutics landscape for uncomplicated Urinary Tract Infection across the 7MM, spanning the years 2019 to 2032. By delving into this analysis, stakeholders gain valuable insights into the evolving landscape of Sulopenem Etzadroxil/Probenecid, encompassing both clinical and commercial dimensions. Key parameters such as the drug's Mechanism of Action (MOA), Route of Administration (ROA), dosage, and any special designations are meticulously explored, providing a holistic understanding of its profile.

Get a detailed overview of the Sulopenem Etzadroxil/Probenecid drug and stay ahead of the competition by leveraging key insights:
https://www.delveinsight.com/report-store/sulopenem-etzadroxil-probenecid-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Sulopenem Etzadroxil/Probenecid Drug Insights
Iterum Therapeutics is currently in the developmental stages of its pioneering compound, sulopenem. This groundbreaking penem anti-infective agent is being formulated for both oral and intravenous administration. Sulopenem has exhibited remarkable efficacy in laboratory tests, showcasing potent activity against a wide spectrum of bacteria including gram-negative, gram-positive, and anaerobic strains that have shown resistance to conventional antibiotics. Moreover, its orally bioavailable nature makes it a promising candidate for combating infections caused by multidrug-resistant bacteria. As such, Sulopenem represents a significant advancement in the realm of broad-spectrum penem β-lactam antibiotics, offering a potential solution to the challenges posed by antibiotic resistance.

Sulopenem Etzadroxil/Probenecid: Clinical and Commercial Developments
Discovered in the laboratories of Pfizer during the 1980s, sulopenem initially emerged as an intravenous (IV) formulation. Pfizer conducted thorough pre-clinical investigations followed by extensive human trials. Subsequently, an oral formulation was engineered and subjected to rigorous Phase I and Phase II studies. Sulopenem, a parenteral thiopenem, exhibits broad-spectrum antibacterial properties, effectively targeting a wide range of gram-positive and gram-negative bacteria. Notably, it is inactive against Pseudomonas aeruginosa. Furthermore, sulopenem demonstrates considerable stability against hydrolysis induced by various beta-lactamases, bolstering its potential efficacy as a therapeutic agent against bacterial infections.

Currently, Sulopenem is undergoing Phase I clinical investigation subsequent to the successful completion of a Phase III clinical trial targeting the treatment of uncomplicated urinary tract infections (uUTI). The ongoing trial represents a Phase I, multi-center, the open-label study aimed at assessing the safety, tolerability, and pharmacokinetics of both sulopenem and Sulopenem Etzadroxil + Probenecid in adolescent patients afflicted with bacterial infections, including uUTI. Noteworthy is the recent submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) in November 2020 for oral sulopenem, specifically for the management of uUTI in patients harboring quinolone non-susceptible pathogens. However, the FDA has issued a Complete Response Letter (CRL), stipulating the need for supplementary data to substantiate approval for the treatment of adult females with uUTI, thereby rendering it unsuitable for approval in its current state.

Explore key clinical, commercial, and regulatory milestones associated with Sulopenem Etzadroxil/Probenecid by visiting:
https://www.delveinsight.com/report-store/sulopenem-etzadroxil-probenecid-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Key Highlights of the Sulopenem Etzadroxil/Probenecid Market Report
• The report includes a projected assessment of Sulopenem Etzadroxil/Probenecid sales for uncomplicated Urinary Tract Infection up to the year 2032.
• The report offers in-depth coverage of advanced-stage emerging therapies for the treatment of uncomplicated Urinary Tract Infection.
• The report additionally includes both qualitative and quantitative analyses conducted by analysts, along with Key Opinion Leader (KOL) perspectives on Sulopenem Etzadroxil/Probenecid for uncomplicated Urinary Tract Infection.

Why Sulopenem Etzadroxil/Probenecid Market Report?
• The projected market data for Sulopenem Etzadroxil/Probenecid in the context of uncomplicated Urinary Tract Infection will play a crucial role in informing decision-making related to the therapeutic portfolio. It will provide valuable insights into the overall landscape of Sulopenem Etzadroxil/Probenecid, aiding in strategic planning and decision-making processes within the therapeutic domain.
• A comprehensive market forecast for Sulopenem Etzadroxil/Probenecid will contribute to a better understanding of how the drug competes with other emerging therapies within the therapeutics landscape. This analysis will provide insights into the drug's positioning, potential market share, and overall impact on the competitive environment in the therapeutic field.
• The report additionally offers future market assessments for the Sulopenem Etzadroxil/Probenecid market in the field of uncomplicated Urinary Tract Infection across the 7 Major Markets. It encompasses advanced qualitative analyses such as SWOT analysis, insights from expert analysts, a comprehensive overview of market competitors, and a brief analysis of other emerging therapies within the realm of uncomplicated Urinary Tract Infection. This multifaceted approach ensures a comprehensive understanding of the Sulopenem Etzadroxil/Probenecid market landscape, combining both quantitative and qualitative perspectives for a well-rounded assessment.
• Conducting a thorough market forecast for Sulopenem Etzadroxil/Probenecid will facilitate a detailed analysis of the drug's clinical trial progress. This examination will encompass a comprehensive assessment of the clinical, regulatory, and commercial aspects, providing valuable insights into the advancements of Sulopenem Etzadroxil/Probenecid.

Visit and Explore How Sulopenem Etzadroxil/Probenecid Is Set to Dominate the uncomplicated Urinary Tract Infection Therapeutic Market:
https://www.delveinsight.com/sample-request/sulopenem-etzadroxil-probenecid-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Contents of the Report
1. Report Introduction
2. Sulopenem Etzadroxil/Probenecid Overview in uncomplicated Urinary Tract Infection
3. Competitive Landscape (Key Assessment of the Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies Analysis)
5. Sulopenem Etzadroxil/Probenecid Market Assessment
6. SWOT Analysis
7. Analysts' Views
8. Appendix
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
* The final table of contents may be subject to change based on user demand.

Request the Sample PDF to Learn More About the Key Offerings of the Sulopenem Etzadroxil/Probenecid Market Report @
https://www.delveinsight.com/sample-request/sulopenem-etzadroxil-probenecid-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

----------------------------------------------------------------------------------------------------------------------------------

Other Related Reports By DelveInsight
uncomplicated Urinary Tract Infection Pipeline Insight
DelveInsight's "uncomplicated Urinary Tract Infection Pipeline Insight" report provides comprehensive insights about the key companies developing novel drugs in the uncomplicated Urinary Tract Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by routes of administration, and molecule types. Furthermore, it further highlights the inactive pipeline products in this space. Some of the key companies in the uncomplicated Urinary Tract Infection Therapeutics market include GlaxoSmithKline, Iterum Therapeutics, Inmunotek, Janssen Pharmaceuticals, Fimbrion Therapeutics, and others. Visit & explore how the uncomplicated Urinary Tract Infection therapeutics pipeline is evolving, at:
https://www.delveinsight.com/report-store/uncomplicated-urinary-tract-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.